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Overexpression of G1-S regulators cyclin D1 or cyclin A is frequently observed in breast cancer and is also to result in ligand-
independent activation of oestrogen receptor in vitro. This might therefore, provide a mechanism for failure of tamoxifen
treatment. We examined by immunohistochemical staining the effect of deregulation of these, and other cell cycle regulators
on tamoxifen treatment in a group of 394 patients with early stage breast cancer. In univariate analysis, expression of cyclin A,
Neu, Ki-67 index, and lack of OR expression were signiﬁcantly associated with worse prognosis. When adjusted by the clinical
model (for lymph node status, age, performance status, T-classiﬁcation, grade, prior surgery, oestrogen receptor status and
tamoxifen use), only overexpression of cyclin A and Neu were signiﬁcantly associated with worse prognosis with hazard ratios
of, respectively, 1.709 (P=0.0195) and 1.884 (P=0.0151). Overexpression of cyclin A was found in 86 out of the 201 OR-
positive cases treated with tamoxifen, and was the only independent marker associated with worse prognosis (hazard ratio
2.024, P=0.0462). In conclusion, cyclin A is an independent predictor of recurrence of early stage breast cancer and is as such
a marker for response in patients treated with tamoxifen.
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The signalling pathway of oestrogen receptor-a, OR-a, is a major
determinant in human breast tumorigenesis (Brown et al, 1999).
This assumption is derived from observations that OR-a is only
present in a minority of normal breast epithelial cells, whereas
470% of human breast cancer contain OR-a (Ricketts, 1991).
Moreover, oestrogen causes proliferation of OR positive breast
cancer cells (Chalbos et al, 1982). The mitogenic activity of oestro-
gen is still far from being fully understood. Oestrogen induces rapid
changes in cell cycle progression kinetics and results in altered
expression of cell cycle markers in oestrogen responsive cells
(Musgrove et al, 1993; Altucci et al, 1996; Foster and Wimalasena,
1996). These involve key transitions in the eukaryotic cellular divi-
sion, which are controlled by the sequential activation and
inactivation of cyclin dependent protein kinases (cdk). The activity
of these kinases is regulated by phosphorylation/dephosphorylation,
subcellular trafﬁc mechanism, association with cyclin proteins and
with speciﬁc cdk-inhibitors, and by proteolytic degradation (Sherr
and Roberts, 1999). Of these cyclin-cdk complexes, cyclin D-cdk4/
6 activity drives cells through the early G1 phase of the cell cycle,
whereas cyclin E-cdk2 and subsequently cyclin A-cdk2 activities
are required for transition through the later G1 phase of the cell
cycle past the restriction point up to which growth factor stimula-
tion is mandatory. The mitogenic activity of oestrogen involves
stimulation of expression of cyclin D1 (Altucci et al, 1996; Sabbah
et al, 1999) and of cdc25A (Foster et al, 2001) an activating phos-
phatase of cdk2 (Jinno et al, 1994). Inhibition of oestrogen
receptor activity by anti-oestrogens leads to reduced cyclin D1
expression and, as a consequence thereof, to a release of cdk-inhibi-
tors p21 and p27 from the cyclin D-cdk4/6 complex that then
become associated with cyclin-cdk2 complexes. This shift of cdk-
inhibitors results in a cell cycle block in mid-G1 (Planas-Silva and
Weinberg, 1997; Prall et al, 1997). A direct effect of anti-oestrogens
on effectors of the cell cycle downstream of cyclin D1 can, however,
not be excluded (Cicatiello et al, 2000; Foster et al, 2001).
Anti-oestrogens compete with oestrogen for binding to the OR,
but fail to induce receptor activation. These molecules interfere
with multiple steps in the OR signalling pathway, including disso-
ciation from chaperone proteins, nuclear translocation,
dimerization and targeting to OR speciﬁc DNA elements and bind-
ing to transcriptional co-regulators (Osborne et al, 2000). Because
of their ability to disrupt OR signalling pathways, anti-oestrogens
are widely used for the treatment of hormone-dependent breast
cancer. The non-steroidal triphenyl-ethylene anti-oestrogen tamox-
ifen has been established as the ﬁrst choice for adjuvant therapy of
oestrogen-receptor positive breast cancer (Early Breast Cancer
Trialist’s Collaborative Group, 1998; Yao and Jordan, 1999).
OR-a signalling activity is not only induced by oestrogen, but
OR-a is also activated as a transcriptional transactivator in a
hormone-independent manner by phosphorylation of serines 104/
106 by cyclin A-cdk2 (Rogatsky et al, 1999) and by direct binding
of OR-a to cyclin D1 (Zwijsen et al, 1997). Both of these modula-
tions affect the association between OR-a and co-activators of OR-
a (Rogatsky et al, 1999; Zwijsen et al, 1999) and may thereby affect
the ability of anti-oestrogens to inhibit OR-a activity. It has, there-
fore, been hypothesized that tamoxifen treatment of breast cancer
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www.bjcancer.commay be inefﬁcient in tumour cases that harbour genetic lesions
which result in elevated levels of cyclin D1 or A, or that lead to
reduced levels of cdk inhibitors p21 or p27 (Michalides, 1999;
Cariou et al, 2000). We have addressed this hypothesis by examin-
ing the effect of an altered expression of these cell cycle regulators
on the outcome of tamoxifen treatment of patients with early stage
of breast cancer.
MATERIALS AND METHODS
Patients and tumour specimens
The marker group of 394 patients is part of a clinical Comprehen-
sive Cancer Center Amsterdam (IKA) Tamoxifen study on the
effect of adjuvant tamoxifen treatment in breast cancer. Between
1982 and 1994, 1662 patients were randomized in a 2:1 distribu-
tion to control or tamoxifen (30 mg day
71). Patients were eligible
if they were post-menopausal, less than 76 years of age and had a
T1–4,N 0–3, M0 breast tumour (World Health Organization, 1981),
but no mastitis or palpable supra- or infraclavicular lymph nodes.
Randomization was stratiﬁed by institute and nodal status (N+/
N7). After 1989, based on two interim analyses showing a signiﬁ-
cant improvement in progression-free survival in node positive
patients, these patients skipped the ﬁrst randomization and all
received 1 year of tamoxifen. After 1 year they were again eligible
for the second randomization in the study to receive either another
2 years of tamoxifen or to stop further treatment (Figure 1). The
patient characteristics and clinical outcome of tamoxifen treatment
of the original study group (1662 patients) have been presented
elsewhere (Vermorken et al, 1998). Of the patients in this trial,
parafﬁn embedded material was available from a randomly
sampled group of 394 patients. Tissues had been ﬁxed for at least
24 h in neutral buffered 4% formaldehyde. After parafﬁn embed-
ding, 4-mM-thick sections were cut and attached on silane-coated
slides. All tumours used in the marker study were examined by
one pathologist (PvD), were classiﬁed according to WHO criteria
(World Health Organization, 1981) and were graded according to
a modiﬁcation of Bloom and Richardson’s method (Elston and
Ellis, 1990). During the clinical study, oestrogen receptor status
was determined routinely by the dextran-coated charcoal assay
on tumour cytosols. Receptor levels of 410 fmol mg
71 of cytoso-
lic protein were considered positive. Tumours were also examined
for oestrogen receptor by immunohistochemistry.
Immunohistochemistry
Immunohistochemistry was performed as described previously
(Michalides et al, 1996; van Diest et al, 1997). In all cases, except
for staining with anti-Neu, antigen retrieval was applied by micro-
wave treatment in citrate buffer pH 6. Slides were blocked with
10% normal serum, depending on the ﬁrst antiserum to be used,
and were incubated overnight with the following antisera and
dilutions: from Novacastra (Newcastle, UK): cyclin D1 (clone
DCS-6, 1:40); cyclin A (clone 6E6, 1:200), epidermal growth
factor receptor, EGF-R (clone EGFR.113, 1:20); from Pharmingen
(San Diego, USA): p21 (clone 6B6, 1:500); from Transduction
Laboratories (Lexington, USA): p27 (clone K2052, 1:200); from
Dako (Glostrup, Denmark): OR (clone OR1D7, 1:50), progester-
one receptor, PgR (cl PgR 636, 1:100), p53 (clone DO-7, 1:500);
from Immunotech SA (Marseille, France): Ki-67 (Mib1, 1:40).
Anti-Neu antibody was obtained from M vd Vijver (The Nether-
lands Cancer Institute, Amsterdam, The Netherlands) and was
used at a dilution of 1:1000. All ﬁrst antibodies were incubated
overnight at 48C, except for anti-EGFR that was incubated at
room temperature.
Biotinylated second antibodies (Dako, Glostrup, Denmark) were
applied for 30 min at room temperature, after which peroxidase-
conjugated streptavidin-biotin labelling and subsequent DMBA
staining was performed.
The slides were independently examined by two observers (PvD
and RM). For staining of EGFR and Neu only, membrane staining
was considered as positive staining. With the other markers, cells
were considered to be positive only when distinct nuclear staining
was identiﬁed. The percentage of immunoreactive cells was evalu-
ated by scanning whole sections at medium and high
magniﬁcations. p27 expression was scored as low (550% reacting
cells) and high (450%). Scores for positivity for cyclins D1 and E,
OR, PgR, Ki-67, p21 and p53 were determined semi-quantitatively
as described in Materials and Methods. The threshold for positivity
for cyclin A staining was determined from analyzing the Martingale
residuals of cyclin A positives with recurrence as the outcome.
Above 5%, which was also the median value of cyclin A, excess
in risk for recurrence was observed. The range of cyclin A positive
cells in this series ranged from 0–50%, with an average of 9.5%.
Cyclin D1, OR, PgR and Ki-67 were considered positive if 45%
of the cells stained, for cyclin A expression 410% of the cells
staining was considered as positive. All cases expressing cyclin E,
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Study design
Stratification
•Axill. Nodal Status*
•Participating Centre
Tamoxifen
1 year 3´10mg
STOP
Tamoxifen
+2 years
Tamoxifen
Control
no treatment*
R1
R2
*Based on an interim analysis in 1989, patients with positive nodal status were no
longer randomized to treatment or no treatment. They were stratified to the treatment
arm, only to be randomized after 1 year to cessation of tamoxifen or continuation
up to 3 years
Patients
Between July 1982 and February 1994, a total of 1662 patients entered the study.
1242 patients were randomized to Tamoxifen or no treatment (R1) and 991 patients
were randomized to another 2 years of tamoxifen or to stop further treatment (R2).
Figure 1 Design of the IKA Tamoxifen study.
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earlier settings of (Michalides et al, 1996; van Diest et al, 1997;
Barbareschi et al, 2000).
Statistical analysis
The endpoint for analysis was recurrence, deﬁned as the ﬁrst reap-
pearance of breast cancer at any site (local, contralateral, or
distant). Survival estimates and curves were calculated with the
Kaplan-Meier technique and differences in time to recurrence were
tested by means of a log-rank test. To estimate the association of
markers with time to recurrence adjusted for other (known) clini-
cally important variables, Cox proportional hazard analysis was
used. The model for adjustment consisted of the following vari-
ables: lymph node status (N0, N+), Age (continuous), Karnofski
performance index (580, 80–100), T-classiﬁcation (T1, T2, T3,
T unknown), histological grade (grade I, grade II, grade III), OR
status (OR+, OR-, OR unknown), and breast conserving surgery
or mastectomy. The association between each of the clinicopatho-
logical markers individually was analyzed by Spearman rank
correlation.
RESULTS
Baseline characteristics of the IKA tamoxifen trial patients who also
participated in the marker study are shown in Table 1. The median
follow-up is almost 10 years in the tamoxifen study and over 8
years in the marker study. In 108 patients of the 394 patients in
the marker study (27%), breast cancer reappeared. The associations
between clinical and pathological parameters and recurrence were
as to be expected. The great majority of the 394 patients (320;
81%) had received tamoxifen. Tamoxifen showed to be signiﬁ-
cantly associated with a better prognosis in the original trial
group of 1662 patients (hazard ratio (HR)=0.66, 95% CI 0.55–
0.80, P=0.0001), but a similar effect seen in the marker study group
of 394 patients was not signiﬁcant (HR=0.66, 95% CI 0.39–1.13,
P=0.127).
The results of the marker studies and their association with time
to recurrence are presented in Tables 2 and 3. Nuclear staining was
also observed together with a weak positive cytoplasmic staining in
some of the cyclin A positive tumour cells. This may well indicate
cells at G2 phase of the cell cycle. In univariate analysis, expression
of cyclin A and Neu, high Ki-67 index, and lack of OR expression
were signiﬁcantly associated with worse prognosis. When adjusted
by the clinical model (for lymph node status, age, performance
status, T-classiﬁcation, grade, prior surgery, oestrogen receptor
status and tamoxifen use), only overexpression of cyclin A and
Neu were signiﬁcantly associated with worse prognosis with HR
of, respectively, 1.709 (P=0.0195) and 1.884 (P=0.0151), see also
Figure 2. None of the other markers used were independent indi-
cators of prognosis, including cyclin D1, cyclin E, p53, p21, p27,
and EGF-R.
Table 4 summarizes the relationship between cyclin A expression
and the other markers.
Cyclin A overexpression was signiﬁcantly associated with overex-
pression of Neu, Ki-67, with expression of p53, with absence of
OR, with high histological grade and high T-classiﬁcation. Alto-
gether, these associations suggest that overexpression of cyclin A
is more frequently found in large size, undifferentiated, OR-nega-
tive breast tumours with an increased proliferative fraction. A
representative cyclin A staining in breast cancer cells is given in
Figure 3.
To analyze which of the markers studied contributed to a more
inefﬁcient treatment with tamoxifen, we examined a more
restricted group of OR positive breast cancer patients treated with
tamoxifen, presuming that any effect should be eminent here.
Overexpression of cyclin A was the only independent marker asso-
ciated with a worse prognosis in tamoxifen treated OR-positive
tumours, with a HR of 2.024 (P=0.0462). Cyclin A overexpression
was found in 86 out of 201 OR-positive cases that were treated
with tamoxifen.
DISCUSSION
Cyclin D1 and cdc25A behave as oestrogen-sensitive oncogenes
(Altucci et al, 1996; Sabbah et al, 1999; Foster et al, 2001). Intro-
duction of these genes in murine ﬁbroblasts contributes to
cellular transformation, and genetic alterations leading to increased
expression of these genes are frequently observed in breast cancer
(Quelle et al, 1993; Galaktionov et al, 1995; Michalides, 1999;
Cangi et al, 2000). Mice transgenic for cyclin D1 are prone to
tumour development, the type of tumour being dependent on
the enhancer sequence used to construct the cyclin D1 transgene
(Bodrug et al, 1994; Wang et al, 1994; Robles et al, 1996).
However, neither overexpression of cyclin D1 or of cdc25A was
found to be an independent indicator of prognosis in early stage
breast cancer (Michalides et al, 1996; van Diest et al, 1997; Cangi
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Table 1 Patient and tumour characteristics of the sample study of 394
patients
Marker sample
Recurrence log-
Characteristics n % rank P-value
All patients 394 100.0
Age
560 years 99 25.1
60–70 years 208 52.8
470 years 87 22.1 0.2675
Performance status
100 338 85.8
80–90 54 13.7
60–70 2 0.5 0.6975
Prior surgery
Radical 230 58.4
Conservative 159 40.4
Other 5 1.3 (global) 0.0066
Nodal status
N0 231 58.6
N+ 163 41.4 50.0001
T-classiﬁcation
Tx 8 2.0
T1 142 36.0
T2 212 53.8
T3 27 6.9
T4 5 1.3 (global) 50.0001
Histological grade
No data 52 13.2
Grade I 105 26.6
Grade II 129 32.7
Grade III 108 27.4 (global) 0.0126
Oestrogen receptor
a
OR+ 247 62.7
OR7 139 35.3
OR? 8 2.0 0.0254
Treatment
No Tamoxifen 74 18.8
Tamoxifen
b 320 81.2
Disease status
Alive, no recurrence
c 250 63.5
Alive with recurrence 30 7.6
Dead with recurrence 78 19.8
Dead, other causes 36 9.1
aOestrogen receptor status was determined by immunohistochemistry;
bTamoxifen
use varies from 1–3 years;
cRecurrence is deﬁned as the ﬁrst appearance of
breast cancer at any site (local, contralateral or distant).
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overexpression of cyclin D1 does not affect the outcome of tamox-
ifen treatment of early stage, OR-a positive breast cancer. Although
we did not study directly expression of cdc25A in these tumours,
we found that overexpression of cyclin A is signiﬁcantly associated
with worse outcome in tamoxifen treated patients (P=0.0462). In
the whole group of patients, including 247 OR-positive, 139 OR-
negative and eight OR-unknown cases, overexpression of cyclin A
and of Neu were indicative of worse outcome, with P values of
0.0195 and 0.0151 respectively (Table 3). Neu overexpression
already has previously been reported to be associated with a worse
prognosis (Slamon et al, 1987) and more recently was found to be
indicative of tamoxifen resistance (Houston et al, 1999; Stal et al,
2000). The prognostic value of cyclin A overexpression may well
be contributed to its interaction with large sized, undifferentiated,
OR-negative breast tumours with an increased proliferative capa-
city (Table 4). However, also in the group of OR-a-positive
breast cancers, cyclin A overexpression did behave as an indepen-
dent marker of worse prognosis. In our study, overexpression of
p53, indicative of p53 mutation, was not associated with outcome
of disease or tamoxifen treatment. Only speciﬁc p53 mutations,
determined by sequencing of the p53 gene, are most informative
in predicting response to systemic therapy of advanced breast
cancer (Berns et al, 2000), whereas we examined early stage breast
cancer by p53 immunohistochemistry, which is less accurate in
detecting mutations.
We hypothesized that cyclin D1 and/or cyclin A might affect
outcome of tamoxifen treatment, since both cyclins are
hormone-independent activators of OR-a in in vitro experiments
(Zwijsen et al, 1997; Rogatsky et al, 1999). Cyclin D1 does so by
binding to OR-a and thereby enhances the interaction between
OR-a and SRC (steroid receptor coactivator)-1 (Zwijsen et al,
1999), whereas cyclin A-cdk2 phosphorylates cdk2 at serines
104/106 (Rogatsky et al, 1999), and thereby activates OR-a tran-
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Table 2 Markers: frequency, 5-year survival estimates and log-rank test
Frequency
(%)
% 5-years Log-rank
n % recurrence-free
a P-value
394 100.0
Cyclin D1 (n=363)
7 262 72.2
+ 101 27.8 0.1480
Cyclin E (n=364)
7 361 99.2
+ 3 0.8 0.1698
Cyclin A
7 198 50.3 87
+ 196 49.7 71 0.0011
p53 (n=350)
7 282 80.6
+ 68 19.4 0.1445
p21 (n=385)
7 246 63.9
+ 139 36.1 0.9872
p27 (n=350)
7 107 30.6
+ 243 69.4 0.1928
Ki-67 (n=352)
7 126 35.8 89
+ 226 64.2 73 0.0023
Neu (n=364)
7 317 87.1 82
+ 47 12.9 62 0.0014
EGF-R (n=364)
7 306 84.1
+ 58 15.9 0.1007
OR (n=386)
7 139 36.0 73
+ 247 64.0 83 0.0254
a5-year estimates are only given for markers with a log-rank test P-value 50.05.
Table 3 Markers: HR and 95% CI, univariate and adjusted
Univariate Adjusted
HR 95% CI HR 95% CI P-value
Cyclin D1 0.706 0.440–1.134 0.808 0.487–1.340 0.4089
Cyclin A 1.895 1.284–2.797 1.709 1.090–2.679 0.0195
p53 1.424 0.884–2.294 1.254 0.721–2.184 0.4229
p21 0.997 0.669–1.486 0.940 0.623–1.419 0.7689
p27 0.760 0.503–1.150 0.810 0.525–1.251 0.3426
Ki-67 2.069 1.284–3.333 1.717 0.992–2.969 0.0533
Neu 2.132 1.326–3.427 1.884 1.130–3.139 0.0151
EGF-R 1.495 0.992–2.425 1.1427 0.855–2.381 0.1736
OR 0.647 0.440–0.951
Adjusted for lymph node status, age, performance status, T-classiﬁcation, grade, prior
surgery, oestrogen receptor status and tamoxifen use. HR below 1 indicates a better
prognosis (for increased expression of the marker).
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196 166 136 109 53 15 cA +
115 109 101 83 40 19 cA –
 86 76 62 46 20 7 cA +
A
B
Figure 2 Recurrence-free interval curves for groups of breast cancer pa-
tients (A) with and without overexpression of cyclin A, and (B) OR-posi-
tive breast cancer treated with tamoxifen, with and without overexpression
of cyclin A (log rank P value=0.0462).
Cyclin A in early stage breast cancer
R Michalides et al
405
ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(3), 402–408scriptional activity. The activation of OR-a by these cyclins is
tamoxifen-insensitive, but this depended on in vitro transient
transfection where excess cyclin proteins are being generated.
However, an experimentally induced six-fold overexpression of
cyclin D1 in MCF-7 cells did not render these cells to grow
in the presence of anti-oestrogens (Pacilio et al, 1998). That
ﬁnding and the present study indicate that over-expression of
cyclin D1 as it is being observed under experimental in vitro
transfection conditions, is not likely to be encountered in vivo.
This may only be achieved during lactation where co-stimulation
of protein kinase A together with oestrogens does result in exces-
sive levels of cyclin D1 that activate OR (Lamb et al, 2000). It
should also be mentioned that cyclin D1 is stimulating OR tran-
scriptional activity only when it is free of its regular cdk4/6
partner (Zwijsen et al, 1997), but that free cyclin D1 is more
prone to proteolytic degradation than when bound to cdk4/6
(Diehl et al, 1997). Another confounding factor may be the acti-
vation by cyclin D1 of p21 (Barbareschi et al, 1997; De Jong et
al, 1999).
We applied the immunohistological stainings of cell cycle related
markers on the residual samples available from the original IKA
Tamoxifen study of 1662 patients. In the cohort of 394 patients
which was available for the marker study, tumour recurrence was
still associated with the base-line clinical prognostic parameters
such as grade, stage and lymph node involvement, as was the case
in the original study including 1662 patients, indicating that the
sample used for the present study was representative (Vermorken
et al, 1998). A drawback of this study was the relatively short
period of tamoxifen treatment of the patients during 1 or 3 years,
according to the original setting up of the trial. Recent studies
suggest that tamoxifen should be given for longer periods (prob-
ably 5 years or more) (Early Breast Cancer Trialist’s
Collaborative Group, 1998; Fischer et al, 2001; Steward et al,
2001). In our marker study about 50% of the patients received
tamoxifen for only 1 year and 74 patients did not receive tamoxifen
treatment at all. This shorter period of tamoxifen treatment has
most likely inﬂuenced our results in narrowing the effective
window of tamoxifen treatment. Nevertheless, some putative prog-
nostic indicators for treatment could be identiﬁed in this group of
tamoxifen-treated patients.
Overexpression of cyclin D1 is generally found in OR-a-positive,
more differentiated breast cancer (Gillett et al, 1996; Michalides et
al, 1996; van Diest et al, 1997), whereas overexpression of cyclin
A is associated with OR-a-negative, undifferentiated breast cancer
(this study). In both cases overexpression of the cyclins is associated
with higher proliferation index (Ki-67 staining). The effect of over-
expression of cyclin D1 on the outcome of tamoxifen treatment is
controversial: overexpression of cyclin D1 messenger RNA was
found to be predictive of poor prognosis in lymph node positive,
OR-a-positive breast cancer (Kenny et al, 1999), which would
support the hypothesis raised above. However, other reports indi-
cate that moderate/strong staining of cyclin D1 protein was
associated with complete or partial response to tamoxifen treatment
(Fischer et al, 2001). Our study shows no effect of cyclin D1, neither
on the incidence of recurrence, as was also reported previously
(Michalides et al, 1996), nor on outcome of tamoxifen treatment
within the OR-a-positive group of patients. Since cyclin D1 staining
is associated with OR positivity, overexpression of cyclin D1 is likely
indicating a beneﬁcial response to tamoxifen when all breast cancers,
OR-positive and -negative, are taken together.
Overexpression of cyclin A is associated with undifferentiated,
OR-negative and Ki-67 positive breast tumours, which are general
features of a more aggressive breast tumour phenotype. Overex-
pression of cyclin A protein may represent an increased growth
fraction of the tumour, an elevated expression of cyclin A protein
per tumour cell, or a combination of both. The end result,
increased positivity of a tumour for cyclin A staining, is associated
with poor clinical course. Since cyclin A associated kinase activity is
stimulated by cdc25A, the effect of overexpression of cyclin may
well be redundant with that of cdc25A (Blomberg and Hoffmann,
1999). Interestingly, overexpression of cdc25A is indicative of a
weakly increased risk of dying of disease (Cangi et al, 2000),
whereas cyclin A is a signiﬁcant prognostic indicator of poor prog-
nosis, for OR-positive as well as for OR-negative breast cancer
(Bukholm et al, 2001; this study).
These results and those of others (Nielsen et al, 1999) indicate
that defects in G1 regulation are involved in breast cancer progres-
sion, and that particular defects are indicative of prognosis and of
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Figure 3 (A, B) Immunohistochemical staining of breast cancer with
antibody 6E6 speciﬁc for cyclin A. Note the nuclear staining with a weak
cytoplasmic staining in some of the cyclin A positive tumour cells that
may indicate cells at G2 phase of the cell cycle.
Table 4 Association between cyclin A overexpression and other cell
cycle and related clinical markers in the markers study of 394 breast cancer
patients
Clinical
parameters Cyclin A Markers Cyclin A
Age
SCC 70.14570 Cyclin D1 70.12117
P 0.0038 0.0209
n 394 363
Lymph node status
SCC 70.06564 Cyclin E 0.17716
P 0.1935 0.0007
n 394 364
T-classiﬁcation
SCC 0.13207 p53 0.21151
P 0.0087 50.001
n 394 350
Histological grade
SCC 0.59041 p21 0.01480
P 50.0001 0.7722
n 342 385
OR receptor
SCC 70.26015 p27 70.16851
P 50.0001 0.0016
n 386 350
Ki-67
SCC 0.70909
P 0.0001
n 352
NEU
SCC 0.14901
P 0.0044
n 364
EGFR
SCC 0.18999
P 0.0003
n 364
A positive coefﬁcient indicates a positive association with overexpression of Cyclin A.
SCC: Spearman correlation coefﬁcient.
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icance of these associations with prognosis suggests, however, that
other interactive factors are involved. This study and that of Cangi
et al (2000) provide evidence that the anti-mitogenic effects of
anti-oestrogens are also in vivo to be overcome by mechanisms that
affect cdk2 activation and cyclin A expression. Patients with such a
primary breast cancer may therefore, beneﬁt from other treatments,
for instance from chemotherapy or potential cdk2 inhibitors. We
found that cyclin A overexpression is indicative of a poor prognosis
in early stage breast cancer and may therefore, serve to further
differentiate therapy in both tamoxifen-treated and non-treated
patients.
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APPENDIX
Participating hospitals in the IKA trial (CKTO 8209) were: Medisch
Centrum Alkmaar, Alg. Chr. Ziekenhuis Eemland (Amersfoort), Acade-
misch Medisch Centrum (Amsterdam), Antoni van Leeuwenhoek
Ziekenhuis (Amsterdam), Onze Lieve Vrouwe Gasthuis (Amsterdam), Vrije
Universiteit Medisch Centrum (Amsterdam), Rode Kruis Ziekenhuis
(Beverwijk), Ziekenhuis Gooi Noord (Blaricum), Gemini Ziekenhuis (Den
Helder), Deventer Ziekenhuis, Albert Schweitzer Ziekenhuis (Dordrecht),
Kennemer Gasthuis (Haarlem), Streekziekenhuis Coevorden-Hardenberg
(Hardenberg), Spaarne Ziekenhuis (Heemstede), Streekziekenhuis Midden-
Twente (Hengelo), Ziekenhuis Hilversum, Westfries Gasthuis (Hoorn),
IJsselmeerziekenhuizen (Lelystad), St. Antonius Ziekenhuis (Nieuwegein),
Medisch Spectrum Twente, locatie Oldenzaal, Waterlandziekenhuis
(Purmerend), Diakonessenhuis (Utrecht), Universitair Medisch Centrum
Utrecht, Streekziekenhuis Koningin Beatrix (Winterswijk).
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